UIC Law Review Volume 22 Issue 3 Article 5 Spring 1989 Federal Preemption of Prescrption Drug Labeling: Antidote for Pharmaceutical Industry Overdosing on State Court Jury Decisions in Products Liability Cases, 22 J. Marshall L. Rev. 629 (1989) John F. Del Giorno Follow this and additional works at: https://repository.law.uic.edu/lawreview Part of the Common Law Commons, Constitutional Law Commons, Consumer Protection Law Commons, Food and Drug Law Commons, Health Law and Policy Commons, Legislation Commons, Medical Jurisprudence Commons, State and Local Government Law Commons, and the Torts Commons Recommended Citation John F. Del Giorno, Federal Preemption of Prescrption Drug Labeling: Antidote for Pharmaceutical Industry Overdosing on State Court Jury Decisions in Products Liability Cases, 22 J. Marshall L. Rev. 629 (1989) https://repository.law.uic.edu/lawreview/vol22/iss3/5 This Comments is brought to you for free and open access by UIC Law Open Access Repository. It has been accepted for inclusion in UIC Law Review by an authorized administrator of UIC Law Open Access Repository. For more information, please contact
[email protected]. COMMENTS FEDERAL PREEMPTION OF PRESCRIPTION DRUG LABELING: ANTIDOTE FOR PHARMACEUTICAL INDUSTRY OVERDOSING ON STATE COURT JURY DECISIONS IN PRODUCTS LIABILITY CASES I. INTRODUCTION As a society, Americans insist on the best available medications to treat those suffering from illness. In response to this demand, Congress has entrusted the Food and Drug Administration ("FDA")' with the responsibility to ensure that drugs marketed in the United States are both safe and effective.' Pursuant to the fed- eral Food, Drug and Cosmetic Act("FDCA"),3 the FDA is the sole decision maker concerning the safety and efficacy of drugs marketed in the United States.4 Ultimately, every aspect of drug formulation, production, testing, and labeling is overseen through the compre- hensive regulatory efforts of this agency.5 1.